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ABSTRACT
Background: The multicountry Women First trial demonstrated that
nutritional supplementation initiated prior to conception (arm 1) or
early pregnancy (arm 2) and continued until delivery resulted in
significantly greater length at birth and 6 mo compared with infants
in the control arm (arm 3).
Objectives: We evaluated intervention effects on infants’ longitudinal growth trajectory from birth through 24 mo and identified
predictors of length status and stunting at 24 mo.
Methods: Infants’ anthropometry was obtained at 6, 12, 18, and
24 mo after the Women First trial (registered at clinicaltrials.gov
as NCT01883193), which was conducted in low-resource settings:
Democratic Republic of Congo, Guatemala, India, and Pakistan.
Longitudinal models evaluated intervention effects on infants’
growth trajectory from birth to 24 mo, with additional modeling used
to identify adjusted predictors for growth trajectories and outcomes
at 24 mo.
Results: Data for 2337 (95% of original live births) infants were
evaluated. At 24 mo, stunting rates were 62.8%, 64.8%, and 66.3%
for arms 1, 2, and 3, respectively (NS). For the length-for-age zscore (LAZ) trajectory, treatment arm was a significant predictor,
with adjusted mean differences of 0.19 SD (95% CI: 0.08, 0.30;
P < 0.001) and 0.17 SD (95% CI: 0.07, 0.27; P < 0.001) for arms 1
and 2, respectively. The strongest predictors of LAZ at 24 mo were
birth LAZ <–2 and <–1 to ≥–2, with adjusted mean differences of
–0.76 SD (95% CI: –0.93, –0.58; P < 0.001) and –0.47 SD (95% CI:
–0.56, –0.38; P < 0.001), respectively. For infants with ultrasounddetermined gestational age (n = 1329), the strongest predictors of

stunting were birth LAZ <–2 and <–1 to ≥– 2: adjusted relative risk
of 1.62 (95% CI: 1.39, 1.88; P < 0.001) and 1.46 (95% CI: 1.31,
1.62; P < 0.001), respectively.
Conclusions: Substantial improvements in postnatal growth are
likely to depend on improved intrauterine growth, especially during
early pregnancy.
Am J Clin Nutr 2022;116:86–96.
Keywords: stunting, breastfeeding, growth, infant growth, maternal
height, preconception, birth length

Introduction
The multicountry Women First (WF) trial demonstrated that
comprehensive nutritional supplementation initiated at least 3 mo
prior to conception or at the end of the first trimester resulted
in significantly longer birth length (the primary outcome) and
greater birth weight. Rates of stunting at birth, low birth weight,
and small for gestational age were also significantly reduced in
the intervention arms compared with a nonintervention control
group (1). Despite the nutrition intervention being stopped at
delivery, the favorable growth effects on linear and ponderal
growth were sustained through 6 mo, and stunting rates at
6 mo were lower for the preconception and early pregnancy
intervention arms (2). The plausibility of these observations is
supported by recognition that the physiologic processes during
early gestation are particularly critical for linear growth, have
long-term programming effects, and are exquisitely sensitive to
maternal nutritional status and well-being (3, 4).
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the original work is properly cited.

86

Downloaded from https://academic.oup.com/ajcn/article/116/1/86/6604747 by oup user on 12 August 2022

Birth length is the strongest predictor of linear growth status and
stunting in the first 2 years of life after a preconception maternal
nutrition intervention: the children of the Women First trial

Predictors of stunting at 2 years

Methods
Study design and settings
This analysis included prospectively obtained anthropometry
of those live-born infants of the women in the WF trial
(registered at clinicaltrials.gov as NCT01883193) who had birth
measurements and who consented to the follow-up growth
monitoring study at 6 mo and continued through 24 mo postnatal
age. Growth from birth to 6 mo was an a priori secondary outcome
of the primary trial, and results have been reported elsewhere (1,
2). In this report, we examined infants’ trajectory of linear and
ponderal growth over the entire interval from birth through 24 mo
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according to treatment arm of the mother, and we determined
predictors of linear growth status at 24 mo.
The original trial was a multisite, individually randomized,
clinical trial in which nonpregnant women were randomly
assigned to 1 of 3 arms: initiation of a daily small quantity
lipid-based nutrient supplement (SQ-LNS) at the time of
randomization with continuation for at least 3 mo prior to
conception through to delivery (arm 1), initiation of the same
supplement late in the first trimester of pregnancy and continued
through to delivery (arm 2), or receipt of no trial supplement (arm
3). Women in arm 1 and arm 2 (once having started the primary
supplement) who were underweight or had inadequate gestational
weight gain were provided an extra protein-energy supplement
until delivery. More than 85% of the participating women in
3 of the sites received the protein-energy supplement; <10%
of the Guatemalan women qualified for the second supplement.
The trial was conducted in low-resource, rural, and small city
settings in 4 countries: Democratic Republic of the Congo
(DRC), Guatemala, India, and Pakistan (1, 8).
Participants
Consent was obtained from the WF participants to be contacted
for ongoing measurements and data collection for their liveborn infants. Birth anthropometric measurements, including
length, weight, and head circumference, were obtained by
study assessment teams by at least 7 d of postnatal life, and
98.2% were obtained within 48 h of birth. Anthropometric
measurements were obtained at 6, 12, 18, and 24 mo of age
between February 2015 and March 2019. Because of interest in
gestational age-dependent covariates [e.g., small for gestational
age (SGA), prematurity], we examined potential predictors
from the subgroup of infants for whom gestational age was
determined by first-trimester ultrasounds; ultrasound capacity
was not available in the DRC.
Randomization
The central data coordinating center (DCC; RTI International)
created the randomization scheme for the original trial, generating the allocation sequence separately for each research site.
To ensure geographic balance, a permuted block design stratified
by geographical clusters was used to generate the randomization
sequence for assigning individual participants to a trial arm.
The allocation ratio was 1:1:1 within blocks, which randomly
varied between sizes of 3, 6, or 9. At each site, once the
responsible home visitor research assistant (HVRA) identified an
eligible participant, the HVRA then received the randomization
assignment from their site-specific data manager, who generated
the randomization assignment from the centralized computerized
data management system maintained by the DCC.
Anthropometry
Length, weight, and head circumference measurements were
obtained by assessment teams who were not directly involved in
administration of the study intervention or any of the home visits
throughout the trial. The assessors were trained and certified
according to standardized procedures and were recertified every
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The potential for persistence of such preconception and prenatal effects on linear growth faltering during the complementary
feeding period, that is, over the second half of the 1000 d, is less
clear. Although declining, the overall prevalence of stunting in
children <5 y of age remains in the 20–25% range, with rates
varying substantially among regions of the globe (5, 6). A recent
“roadmap” to reduce stunting identified multiple health and
nonhealth factors that have been associated with improvements
in postnatal linear growth and reductions in stunting rates. These
factors prominently included several maternal factors, including
improved nutrition (7).
Thus, the goal of the analyses in this report was to determine
whether the benefits of improved maternal nutritional status
prior to conception and during early gestation on fetal and
early postnatal growth were sustained at 2 y. The objectives
of these analyses were 3-fold: 1) to examine postnatal growth
and whether the benefits of the intervention evident at birth
and 6 mo were detectable through the first 24 mo after birth,
2) to identify predictors of the longitudinal growth trajectory
from birth through 24 mo of age, and 3) to identify, in a crosssectional analysis, the major predictors of linear growth status at
24 mo for infants of all participating women and separately for
the subgroup of infants for whom gestational age determinations
were available.
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3 mo. The equipment included electronic balances accurate to 10
g (seca 334; seca North America); nonstretch, plasticized measuring tapes (seca 201; seca North America); and length boards
accurate to 1 mm (neonatal and pediatric stadiometers; Ellard
Instrumentation, Ltd). The z-scores, which accounted for sex and
age at the time of measurement, were calculated for length-forage z-score (LAZ), weight-for-age z-score (WAZ), weight-forlength z-score (WLZ), and head circumference-for-age z-score
from the WHO Child Growth Standards (9). For women who had
first-trimester ultrasounds performed, the gestational age-specific
birth anthropometric z-scores were also determined based on
INTERGROWTH-21st fetal growth charts (10).

The project was approved by the Colorado Multiple Institutional Review Board, University of Colorado; the local and/or
national ethics committees for each of the 4 sites (registered with
the US Office of Human Research Protection and with federalwide assurance in place); and the DCC (RTI International).
Written informed consent was obtained from all participants. The
study protocol is available online: https://www.ncbi.nlm.nih.gov
/pmc/articles/PMC4000057/. Throughout the intervention phase
of the trial, a data monitoring committee designated by the Eunice
Kennedy Shriver National Institute of Child Health and Human
Development monitored the safety of the trial. Adverse events
that were monitored included pregnancy outcomes, adverse
neonatal events, hospitalizations, and allergic reactions (1, 8).
Statistics
Overall approach and model selection.
For all the adjusted models, collinearity of independent
variables was examined using Spearman and Pearson correlation
coefficients for discrete and continuous variables, respectively.
In addition to reviewing the correlations, R2 and comparisons of
log-likelihoods were also considered for final model selection. In
addition, interactions between arm and site, sex and arm, and arm
and parity were examined.
Some of the continuous predictors (height and BMI) were
categorized based on the cutoff values identified by classification
and the regression tree algorithm. Paternal variables were missing
for ∼15.5% infants. A separate category for the missing values
was created to include these records in all the final models.
Paternal height was categorized as a 3-group variable: ≤160 cm,
>160 cm, and missing. Similarly, paternal BMI (in kg/m2 ) was
categorized as ≤24, >24, and missing.
Two-sided P values were reported throughout, with P < 0.05
considered statistically significant. Statistical analyses were
conducted using SAS 9.4 statistical software (SAS Institute).
Maternal treatment effects on postnatal longitudinal growth.
After excluding biologically implausible anthropometric measurements (length and head circumference) according to WHO
guidelines, the longitudinal analysis included all live-born infants
with birth length measurements obtained by 7 d of age who were
alive at 6 mo and whose parents had provided consent for followup to 2 y. We constructed longitudinal models using generalized

Predictors of longitudinal growth trajectory.
A second series of longitudinal GEE models were fit on the
same data to identify the predictors of the longitudinal growth
trajectory from birth through 24 mo, adjusting for treatment
arm. These models also adjusted for maternal and paternal BMI
and height. In addition, interactions between arm and site, arm
and visit, sex and arm, and arm and parity were examined and
included in the final model, as appropriate.

Predictors of linear growth status at 24 mo.
We used cross-sectional analyses, linear (robust Poisson)
regression for continuous (binary) outcomes, to identify the major
predictors of linear growth status at 24 mo. First, for the allsite analysis, the following potential predictors were considered:
SES; maternal education, parity, stunting, height, and BMI;
paternal height and BMI; and birth measurements of length, LAZ,
and stunting, categorized as none (LAZ ≥–1), mild (LAZ <–1 to
≥–2), or moderate (LAZ <–2), and weight, WAZ, WAZ <–2,
weight-for-length, WLZ, WLZ <–2, sex, and low birth weight
(LBW) using WHO growth standards. After model selection,
the final models included arm; site; cluster; interaction between
site and cluster; SES; maternal education, parity, BMI (≤22 and
>22), and height (≤150 cm, >150 cm); and paternal BMI (≤22,
>22, and missing) and height (≤160 cm, >160 cm, and missing).
Separate analyses were conducted for the set of data from
India, Pakistan, and Guatemala with available gestational age
determined by first-trimester ultrasound. The predictors considered were SES; maternal education, parity, stunting, height, and
BMI; paternal height and BMI; and birth measurement z-scores
derived from INTERGROWTH-21st (IG) fetal growth charts (10)
of length; LAZIG ; stunting categorized as categorized as none
(LAZIG ≥–1), mild (LAZIG <–1 to ≥– 2), or moderate (LAZIG
<–2); weight; WAZIG ; WAZIG <–2; weight-for-length; WLZIG ;
WLZIG <–2; SGA; preterm birth (<37 wk of gestation); and sex.
All these predictors were considered in the adjusted models for
each outcome variable. Upon model selection, the final models
included arm; site; cluster; interaction between site and cluster;
SES; maternal education, parity, BMI (≤22 and >22), and height
(≤150 cm, >150 cm); paternal BMI (≤22, >22, and missing)
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Ethics

estimating equations (GEEs) to examine whether the trajectory
of growth for study infants from birth through 24 mo age differed
by treatment arms. Baseline maternal characteristics that differed
across the 3 treatment arms, or between infants included or
excluded from the analysis due to missing data, were considered
for inclusion as covariates in these models: socioeconomic status
(SES), maternal education, parity, BMI, height, and stunting.
Model selection approaches described above were used to
develop the final model. Continuous (binary) outcomes assumed
a normal (binomial) distribution with identity (log) link and
an autoregressive correlation structure with robust sandwich
estimator (empirical estimates) to account for infant repeated
measures over time. We examined treatment heterogeneity by
country using interaction terms for arm and country. Interactions
were also examined to assess the stability of treatment effects
over time for each model.

Predictors of stunting at 2 years

and height (≤160 cm, >160 cm, and missing); infant sex; birth
stunting categories; preterm birth; and SGA (not LBW).

Results

Maternal treatment effects on postnatal longitudinal growth
Means (SDs) of unadjusted anthropometry at 0, 6, 12, and
24 mo and pairwise comparisons among arms are presented in
Supplemental Table 1. After only modest decline in mean LAZ
from birth through 6 mo, the mean LAZ for all arms declined
sharply between 6 and 12 mo, with further decline between 12
and 24 mo (Figure 1). At birth, 6, 12, and 18 mo, mean LAZ
for arm 1 remained significantly greater than the means for arm
3 by pairwise comparisons; mean LAZ for arm 2 was greater
than that of arm 3 only at birth and 6 mo. Similar declines,
although less steep, were observed for WAZ. The overall rates of
stunting progressed from 22.0–30.4% at 6 mo to 62.8%, 64.8%,
and 66.3% for arms 1, 2, and 3, respectively, at 24 mo. By
site, the mean stunting rates were 73.8%, 65.1%, 74.7%, and
45.5% for the DRC, Guatemala, Pakistan, and India, respectively
(Supplemental Table 1 and Supplemental Figure 2).
In the adjusted longitudinal models, significant interactions
indicating treatment heterogeneity by site were observed for
length and LAZ, and site-specific adjusted models were thus
used for these 2 outcomes. Significant treatment effects on
linear growth were observed only in the DRC (Supplemental
Table 2), with arm 1 performing better than arms 2 and 3
for both length and LAZ. No other site-specific comparisons
among arms demonstrated statistically significant differences for
linear growth (Supplemental Table 2). For the combined sites’
longitudinal models, arm 1 compared with 3 was significantly
different for weight (P = 0.0281), WAZ (P = 0.0077), and
WLZ (P = 0.0337). Separate models that included the interaction
effects between arm and time of visit generally demonstrated
attenuation of the treatment effects over time (Supplemental
Table 3).

interactions) was the second major objective of this analysis.
For LAZ, the strongest predictor was maternal height >150 cm
(adjusted mean difference 0.54 SD), followed by paternal height
>160 cm, maternal education (secondary), parity ≥1, and male
infant sex (negative adjusted mean difference). Treatment arm
was a significant predictor of linear growth trajectory, with
greater mean difference for both arms 1 and 2 compared with
arm 3 (Table 2). For WAZ over the same period, significant
predictors were similar to those for linear growth. The strongest
predictor of WLZ was baseline maternal BMI (>22); maternal
education (both primary and secondary) was also significantly
and positively associated with WLZ (Table 2).

Predictors of linear growth status at 24 mo
For the third objective, the cross-sectional analyses at 24 mo
for the children from all sites indicated the strongest predictors
of LAZ were moderate and mild stunting at birth with adjusted
mean differences of −0.76 and −0.47 SD, respectively. Maternal
height (>150 cm) was associated with adjusted mean difference
of +0.45 SD. (Table 3). With the inclusion of the birth length
in the model, treatment arm was not a significant predictor.
Other significant predictors associated with higher adjusted mean
difference of LAZ included maternal education (secondary),
paternal height, maternal BMI, and higher SES; those associated
with lower adjusted mean difference included parity (≥1), LBW,
and sex (male) (model R2 = 0.340). Predictors of stunting,
expressed as adjusted RR, included birth LAZ, with both mild and
moderate stunting at birth associated with an adjusted RR of 1.38.
Maternal height (>150 cm) was associated with an adjusted RR
of 0.73; other significant predictors were similar to those for LAZ
(Table 3). Correlations among variables that were examined and
considered for model selection are presented in Supplemental
Table 4.
For the subgroup of infants with gestational age determinations, the strongest predictors of LAZ at 24 mo were also
stunting at birth (LAZ IG <–2 and <–1 to ≥–2), each associated
with significant and negative adjusted mean differences of
–1.12 SD and –0.51 SD, respectively; preterm birth was
associated with an adjusted mean difference of −0.48 SD.
Maternal and paternal heights (≤150 and ≤160 cm, respectively)
were negatively associated, whereas maternal BMI, maternal
education (secondary), and SES were positively associated with
adjusted mean differences (model R2 = 0.432) (Figure 2A).
The strongest predictors of stunting were moderate and mild
stunting at birth, with adjusted RR of 1.62 and 1.46 , respectively
(Figure 2B). Low parental heights and preterm birth were
also associated with an increased risk of stunting, with RR
between 1.15 to 1.38. Maternal education and BMI >22 were
significant predictors of lower risk of stunting (Figure 2B).
Correlations among variables that were examined and considered for model selection are presented in Supplemental
Table 5.

Discussion
Predictors of longitudinal growth trajectory
Determination of demographic predictors of the longitudinal
growth trajectory from birth through 24 mo (regardless of any

The most striking findings of the present analysis of growth
status at 2 y of the children of participants in the WF trial were the
severe stunting rates; evidence of persistence of a treatment effect
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This analysis is based on infants born to 2324 women who
participated in the primary WF trial and consented to the followup study, for which enrollment and randomization occurred
between December 2013 to October 2014 (Supplemental Figure
1). Baseline characteristics for the mothers and fathers of the
infants and young children of the present analyses are presented
in Table 1. No differences among arms were evident except that
arm 1 had a higher percentage of women with no education and
a higher percentage of nulliparous women. The total number
of infants considered for the combined site analysis was 2337
(95% of original live births), evenly distributed across arms and
sex, with 755, 808, and 774 in arms 1, 2, and 3, respectively
(Supplemental Figure 1), and with 1162 males and 1175 females.
For the subgroup of infants with gestational age determinations,
1329 infants (Guatemala, 439; India, 487; Pakistan, 403) were
included; sample sizes according to treatment arm were 438, 478,
and 413 for arms 1, 2, and 3, respectively.
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TABLE 1 Baseline characteristics among women who had a live birth in the 24-mo longitudinal analysis subset, all sites combined and by treatment arm1
Total

Arm 1

Arm 2

Arm 3

Women who had a live birth in the 24-mo
longitudinal analysis population, n3
Maternal age, n
<20 y
20+ y
Maternal education, n
No formal schooling
Primary
Secondary +
Maternal BMI, n
BMI, kg/m 2 , Mean ± SD
BMI ≤22.0
BMI <18.5
Maternal height, n
Height, cm, Mean ± SD
Height ≤150.0 cm4
Parity, n
0 (nulliparous)
≥1
Paternal height, n
Height, cm, Mean ± SD
Paternal BMI, n
BMI, kg/m 2 , Mean ± SD
Height ≤160.0 cm
Tally of indicators of higher SES5 , n
Median (P25–P75)
Low (0–2 present)
High (3–6 present)

2324

748

806

770

2324
481 (20.7)
1843 (79.3)
2324
746 (32.1)
872 (37.5)
706 (30.4)
2323
21.4 ± 4.0
1509 (65.0)
546 (23.5)
2323
151.4 ± 6.9
995 (42.8)
2324
474 (20.4)
1850 (79.6)
1954
163.5 ± 7.7
1953
22.0 ± 3.7
650 (33.3)
2324
3.0 (1.0, 4.0)
985 (42.4)
1339 (57.6)

748
146 (19.5)
602 (80.5)
748
265 (35.4)
247 (33.0)
236 (31.6)
748
21.4 ± 4.0
493 (65.9)
177 (23.7)
748
151.7 ± 6.5
299 (40.0)
748
179 (23.9)
569 (76.1)
643
163.6 ± 7.9
643
22.1 ± 3.9
209 (32.5)
748
3.0 (1.0, 4.0)
331 (44.3)
417 (55.7)

806
179 (22.2)
627 (77.8)
806
240 (29.8)
313 (38.8)
253 (31.4)
805
21.4 ± 4.1
524 (65.1)
194 (24.1)
805
151.3 ± 7.0
364 (45.2)
806
153 (19.0)
653 (81.0)
666
163.4 ± 7.5
666
21.9 ± 3.7
222 (33.3)
806
3.0 (1.0, 4.0)
332 (41.2)
474 (58.8)

770
156 (20.3)
614 (79.7)
770
241 (31.3)
312 (40.5)
217 (28.2)
770
21.4 ± 3.9
492 (63.9)
175 (22.7)
770
151.3 ± 7.0
332 (43.1)
770
142 (18.4)
628 (81.6)
645
163.5 ± 7.6
644
21.9 ± 3.6
219 (34.0)
770
3.0 (1.0, 4.0)
322 (41.8)
448 (58.2)

P value2

0.398

0.016

0.997
0.710
0.808
0.506
0.111
0.014

0.935
0.605
0.858

0.441

1 Values are presented as number (%) unless otherwise indicated. Arm 1 maternal participants received the study supplement starting at least 3 mo prior
to conception and continued through delivery; arm 2 started the study supplement at the end of the first trimester and continued through delivery; arm 3
(control) did not receive study supplement. SES, socioeconomic status.
2 P values from χ 2 tests and ANOVA analysis to assess for differences between characteristics by treatment arm.
3 Woman had a live birth in the 24-mo longitudinal analysis subset. After excluding extreme invalid measurements as determined by expert manual
review and accounting for biologically implausible z-scores based on WHO standards, the 24-mo longitudinal analysis subset included all live-born infants
with birth length measurements measured by 7 d (168 h) of age on portable length boards and consented to the offspring follow-up study. Extreme invalid
measurements as determined by expert manual review were excluded from the longitudinal analysis. All length-for-age, weight-for-age, weight-for-length,
and head-circumference-for-age z-scores (LAZ, WAZ, WLZ, and HCAZ, respectively) were calculated using the expanded tables of the Child Growth
Standards published by the WHO that provide z-scores by sex and age in days at time of measurement. WLZ were calculated using the expanded tables of the
Child Growth Standards published by the WHO that provide z-scores by sex and tabulated lengths from 45.0 to 110.0 cm. All WHO standards are based on
term infants. LAZ, WAZ, WLZ, and HCAZ were within the biologically plausible range according to WHO standards (–6 ≤ LAZ ≤ 6, –6 ≤ WAZ ≤ 6,
–5 ≤ WLZ ≤ 5, –5 ≤ HCAZ ≤ 5). If an infant was found to have a biologically implausible LAZ or WAZ according to WHO standards at a visit, all growth
outcomes at the visit were set to missing. If an infant was found to have a biologically implausible WLZ or HCAZ according to WHO standards at a visit,
only the corresponding measurement and z-score at the visit were set to missing. WLZ could not be obtained for infants with a length of <45.0 cm at any visit
due to limitations in the WHO standards and were set to missing for that visit (9).
4 This cutoff from the 2007 WHO guidelines (41) was used to reflect stunting for adult women.
5 The SES tally provides the number of indicators available from the following list: electricity, improved water source, sanitation, manmade flooring,
improved cooking fuels, and household assets.

on longitudinal linear growth for the preconception arm, which
was driven predominantly by one site (DRC); that both maternal
and paternal heights were the strongest predictors of longitudinal
linear growth trajectory; and that deficits in birth length were the
strongest predictors of attained LAZ and of stunting at 2 y. With
no postnatal intervention, infants in both maternal intervention
arms experienced a steep decline in LAZ between 6 and 12
mo and a slower but steady downward progression thereafter.
Mild and moderate stunting at birth were associated with 0.5
to 1.0 lower adjusted mean difference in LAZ and a 40–60%
increase in stunting risk at 2 y. Thus, despite the overall pattern
of linear growth faltering for the offspring of mothers in all
arms of the primary trial (1), a smaller length deficit at birth

was associated with a persistent beneficial impact on linear
growth.
The profound stunting rates at 2 y contrast with the steady
decline in global stunting reported in recent analyses, which have
indicated overall declines to ∼20%, although with substantial
variability among and within countries (5, 6, 11). The data
from the WF sites underscore this variability, with rates of
∼65% for the offspring of women in 3 of the study sites and
with the Indian site having a mean rate of 45%. As recently
highlighted (12, 13), the cut-point of 2 SD below the median to
define stunting should not obscure the reality that the observed
mean (and median) LAZ of –2.4 at 24 mo in the WF offspring
portends a high risk for loss of developmental potential for a

Downloaded from https://academic.oup.com/ajcn/article/116/1/86/6604747 by oup user on 12 August 2022

Variable

Predictors of stunting at 2 years

91

very large percentage of the young children in these settings.
The pattern of linear growth faltering we observed indicates little
improvement or even worsening over the past decade for 3 of
the WF sites (DRC, Guatemala, and Pakistan), each of which
participated in a complementary feeding trial a decade ago and
were observed to have stunting rates of ∼50% at 18 mo (14).
A recent analysis of drivers of stunting found that non–health
sector factors accounted for nearly 50% of improvements in
stunting, with improvements in wealth, maternal education, and
urbanization all being associated with lower stunting rates (15).
In contrast, the WF participants bore the hallmarks of stunting
risk—impoverished, undernourished, and poorly educated—and
our results convincingly reinforce the need for multipronged
interventions to reduce stunting.
A major incentive for conducting this follow-up analysis
was to determine the potential for persistence of the benefits
to fetal growth of the preconception and early pregnancy
nutrition intervention on postnatal growth, without any additional
interventions. Although the intervention effects on both linear
and ponderal growth were evident through 6 mo (2), these
follow-up data strongly argue for continued attention to the
remainder of the 1000 d, including complementary feeding.
Qualitative feeding evaluations of the WF offspring indicated
continued breastfeeding but inadequate complementary feeding
for the majority of the infants, especially during the crucial period
between 6 and 12 mo, when energy and nutrient needs remain
relatively high and when we observed the sharpest decline in LAZ
(16). However, nutrition interventions initiated after 6 mo of age
have generally had a modest, if any, impact on linear growth or
rates of stunting in the second year of life (14, 17–23). In addition,
recent intensive interventions to improve water, sanitation, and
hygiene in settings with high stunting rates had virtually no
impact on postnatal linear growth (24). These intervention results
notwithstanding, our observations reinforce the importance of
improving the infant and young child’s nutrition and health
environment. Absent such attention, gains realized in fetal growth
from early maternal interventions seem unlikely to persist past the
early postnatal months.
The analyses for the longitudinal trajectory across the entire
study period identified parental heights (especially maternal) and

intervention arm of the primary trial as significant predictors.
However, with inclusion of birth length in the cross-sectional
analysis at 24 mo, the intervention arm was no longer significant,
and birth length outcomes were the strongest predictors of lower
LAZ and risk of stunting; for the group of infants with gestational
age determinations, moderate stunting at birth had the highest
risk of stunting at 24 mo. Low birth weight (but not SGA) was
a significant predictor but had a considerably smaller impact on
the adjusted mean difference in LAZ at 24 mo compared with
those associated with the deficits in birth length, supporting the
premise that very early fetal growth may program longer-term
linear growth (3, 25). Our observations complement those for a
large cohort of infants in Zimbabwe in whom birth length status,
along with maternal height and education and other factors, was
associated with the pattern and degree of postnatal linear growth
faltering (26).
Among predictive factors, in this analysis and numerous other
studies, maternal height was a robust predictor of the longitudinal
linear growth trajectory and of LAZ and stunting at 2 y (21,
26–29), with height <150 cm associated with a 38% increase
in stunting risk. Maternal height and pelvic dimensions affect
placental dimensions and function, including nutrient transfer,
and are associated with newborn size, including birth length (30)
as well as risk of future chronic conditions (31). In a subgroup
of the WF participants in Pakistan, a high percentage of whom
were stunted and thin, women who received preconception and
first-trimester SQ-LNS (intervention arm 1) had a significantly
larger (+1.4-fold, P = 0.03) placental area than the control
arm, and placental area was correlated with LAZ at birth (32).
This suggests that maternal nutrition during the first trimester
is a modifiable factor with potential to attenuate the growthrestraining effects of maternal short stature. Compared with
maternal height, fewer data on the impact of paternal height are
available, but it is notable that in our study, both paternal height
and BMI were significantly associated with LAZ and stunting at
24 mo. These observations support the increasing recognition of
adolescence as a nutrition-sensitive developmental period and a
window of opportunity to favorably affect adult height for both
women and men, thereby potentially improving reproductive
outcomes (33, 34).
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FIGURE 1 All sites unadjusted longitudinal growth outcomes from birth to 24 mo by treatment arm among the longitudinal analysis subset. Data derived
from Supplemental Table 1. ∗ Indicates unadjusted pairwise comparisons between arm 1 compared with arm 3 were significant. # Indicates unadjusted pairwise
comparisons between arm 2 compared with arm 3 were significant. Total participants by arms 1, 2, and 3, n = 755, 808, and 774, respectively. After excluding
extreme invalid measurements as determined by expert manual review and accounting for biologically implausible z- scores based on WHO standards (9), the
24-mo longitudinal analysis subset includes all live-born infants with birth length measurements measured by 7 d (168 h) of age on portable length boards and
consented to the offspring follow-up study. Arm 1 maternal participants received the study supplement starting at least 3 mo prior to conception and continued
through delivery; arm 2 started the study supplement at the end of the first trimester and continued through delivery; arm 3 (control) did not receive study
supplement. Sample sizes of offspring according to treatment arm were 755, 808, and 774 for arms 1, 2, and 3, respectively. LAZ, length-for-age z-score; WAZ,
weight-for-age z-score; WLZ, weight-for-length z- score.
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TABLE 2 Predictors in models for longitudinal trajectory for linear and ponderal growth for all infants, all sites1
LAZ
Variable

WLZ

Adjusted mean
difference (95% CI)

P value

Adjusted mean
difference (95% CI)

P value

Adjusted mean
difference (95% CI)

P value

0.19 (0.08, 0.30)
0.17 (0.07, 0.27)
Reference

0.001
0.001
Reference

0.11 (0.03, 0.20)
0.05 (–0.03, 0.13)
Reference

0.009
0.215
Reference

0.00 (–0.07, 0.07)
–0.04 (–0.11, 0.04)
Reference

0.996
0.315
Reference

0.46 (0.03, 0.88)
0.56 (0.18, 0.95)
0.45 (−0.05, 0.96)
Reference

0.036
0.004
0.077
Reference

0.02 (–0.39, 0.42)
–0.39 (–0.75, –0.02)
–0.32 (–0.82, 0.17)
Reference

0.931
0.038
0.201
Reference

–0.54 (–0.85, –0.23)
–1.28 (–1.56, –0.99)
–1.12 (–1.56, –0.68)
Reference

0.001
<0.001
<0.001
Reference

0.08 (−0.03, 0.20)
0.26 (0.13, 0.39)
Reference

0.152
<0.001
Reference

0.12 (0.01, 0.23)
0.25 (0.12, 0.37)
Reference

0.033
<0.001
Reference

0.12 (0.02, 0.21)
0.13 (0.02, 0.25)
Reference

0.018
0.018
Reference

0.19 (0.09, 0.29)
Reference

<0.001
Reference

0.27 (0.17, 0.36)
Reference

<0.001
Reference

0.17 (0.09, 0.25)
Reference

<0.001
Reference

0.11 (0.00, 0.22)
Reference

0.043
Reference

0.11 (–0.00, 0.21)
Reference

0.051
Reference

0.05 (–0.04, 0.14)
Reference

0.273
Reference

–0.13 (–0.20, –0.06)
Reference

<0.001
Reference

–0.08 (–0.15, –0.01)
Reference

0.018
Reference

–0.05 (–0.11, 0.01)
Reference

0.125
Reference

0.21 (0.12, 0.29)
Reference

<0.001
Reference

0.26 (0.17, 0.35)
Reference

<0.001
Reference

0.19 (0.11, 0.26)
Reference

<0.001
Reference

0.54 (0.46, 0.63)
Reference

<0.001
Reference

0.39 (0.30, 0.47)
Reference

<0.001
Reference

0.02 (–0.05, 0.09)
Reference

0.638
Reference

0.30 (0.21, 0.39)
Reference

<0.001
Reference

0.20 (0.12, 0.29)
Reference

<0.001
Reference

0.02 (–0.05, 0.10)
Reference

0.565
Reference

0.14 (0.04, 0.23)
Reference

0.004
Reference

0.16 (0.07, 0.25)
Reference

<0.001
Reference

0.09 (0.01, 0.17)
Reference

0.023
Reference

1 All z-scores were calculated using the expanded tables of the Child Growth Standards published by the WHO that provide z-scores by sex and age in
days at time of measurement. Weight-for-length z-scores (WLZ) were calculated using the expanded tables of the Child Growth Standards published by the
WHO that provide z-scores by sex and tabulated lengths from 45.0 to 110.0 cm. All WHO standards are based on term infants. LAZ, WAZ, and WLZ were
within the biologically plausible range according to WHO standards (–6 ≤ LAZ ≤ 6, –6 ≤ WAZ ≤ 6, –5 ≤ WLZ ≤ 5). If an infant was found to have a
biologically implausible LAZ or WAZ according to WHO standards at a visit, all growth outcomes at the visit were set to missing. If an infant was found to
have a biologically implausible WLZ according to WHO standards at a visit, only the corresponding measurement and z-score at the visit were set to missing.
WLZ could not be obtained for infants with a length of <45.0 cm at any visit due to limitations in the WHO standards and were set to missing for that visit
(9). All the final models included the following predictors: treatment arm; site; cluster; interaction between site and cluster; SES; maternal education, parity,
BMI (≤22 and >22), and height (≤150 cm, >150 cm); and paternal BMI (≤22, >22, and missing) and height (≤160 cm, >160 cm, and missing). The
interaction between arm and visit was marginally significant (P value = 0.067) only for LAZ and was included in the final model; interaction effects are not
shown here. Arm 1 maternal participants received the study supplement starting at least 3 mo prior to conception and continued through delivery; arm 2
started the study supplement at the end of the first trimester and continued through delivery; arm 3 (control) did not receive study supplement. Number of
infants considered for the combined site analyses according to treatment arm were 755, 808, and 774 for arms 1, 2, and 3, respectively. LAZ, length-for-age
z-score; SES, socioeconomic status; WAZ, weight-for-age z-score; WLZ, weight-for-length z-score.
2 The SES tally provides the number of indicators available from the following list: electricity, improved water source, sanitation, manmade flooring,
improved cooking fuels, and household assets.
3 Paternal height and BMI had 371 missing records and were included in a separate group: missing group not shown here.

Emphasis on maternal factors is emerging as a critical
and potentially modifiable determinant of child stunting (21),
particularly when improvements in women’s nutrition and overall
health and in environmental factors occur prior to conception
(35). Although both the preconception and end of first trimester
arms of the WF trial demonstrated improved birth length,

several indicators support a greater benefit of the preconception
intervention (compared with no intervention arm) in infants with
gestational age determination, including significantly reduced
risk for moderate stunting and wasting at birth only in the
preconception arm (1, 36); a larger impact on both length
and weight at birth of the preconception arm for nulliparous
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Treatment arm
Arm 1
Arm 2
Arm 3
Site
Guatemala
India
Pakistan
Democratic Republic of the
Congo
Maternal education
Primary
Secondary
No formal schooling
Parity
≥1
0
Tally of indicators of higher SES2
High (3–6 present)
Low (0–2 present)
Sex
Male
Female
Maternal BMI, kg/m2
>22
≤22
Maternal height, cm
>150
≤150
Paternal height,3 cm
>160
≤160
Paternal BMI,3 kg/m2
>24
≤24

WAZ
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TABLE 3 Predictors of LAZ and stunting (LAZ <–2) at 24 mo for all infants, all sites1
LAZ <–2

LAZ
Variable

P value

Adjusted mean
difference (95% CI)

P value

–0.01 (–0.11, 0.09)
–0.04 (–0.14, 0.06)
Reference

0.796
0.419
Reference

1.00 (0.92, 1.09)
1.01 (0.92, 1.10)
Reference

0.983
0.881
Reference

0.16 (0.03, 0.28)
Reference

0.014
Reference

0.94 (0.85, 1.05)
Reference

0.288
Reference

0.10 (–0.03, 0.23)
0.31 (0.16, 0.46)
Reference

0.14
<0.001
Reference

0.94 (0.85, 1.05)
0.79 (0.69, 0.90)
Reference

0.299
0.001
Reference

–0.28 (–0.39, –0.17)
Reference

<0.001
Reference

1.12 (1.02, 1.24)
Reference

0.023
Reference

0.20 (0.10, 0.30)
Reference

<0.001
Reference

0.90 (0.82, 0.99)
Reference

0.031
Reference

0.45 (0.36, 0.55)
Reference

<0.001
Reference

0.73 (0.67, 0.80)
Reference

<0.001
Reference

0.26 (0.16, 0.36)
Reference

<0.001
Reference

0.85 (0.77, 0.92)
Reference

<0.001
Reference

0.08 (–0.03, 0.18)
Reference

0.15
Reference

0.96 (0.87, 1.06)
Reference

0.45
Reference

–0.47 (–0.56, –0.38)
–0.76 (–0.93, –0.58)
Reference

<0.001
<0.001
Reference

1.38 (1.27, 1.49)
1.38 (1.20, 1.60)
Reference

<0.001
<0.001
Reference

–0.11 (–0.28, 0.07)
Reference

0.236
Reference

1.10 (0.93, 1.29)
Reference

0.27
Reference

–0.13 (–0.21, –0.05)
Reference

0.001
Reference

1.10 (1.02, 1.18)
Reference

0.01
Reference

–0.24 (–0.38, –0.10)
Reference

0.001
Reference

1.16 (1.04, 1.30)
Reference

0.01
Reference

1 All z-scores were calculated using the expanded tables of the Child Growth Standards published by the WHO that
provide z-scores by sex and age in days at time of measurement. WLZ were calculated using the expanded tables of the Child
Growth Standards published by the WHO that provide z-scores by sex and tabulated lengths from 45.0 to 110.0 cm. All
WHO standards are based on term infants. LAZ, WAZ, and WLZ were within the biologically plausible range according to
WHO standards (–6 ≤ LAZ ≤ 6, –6 ≤ WAZ ≤ 6, –5 ≤ WLZ ≤ 5). If an infant was found to have a biologically implausible
LAZ or WAZ according to WHO standards at a visit, all growth outcomes at the visit were set to missing. If an infant was
found to have a biologically implausible WLZ according to WHO standards at a visit, only the corresponding measurement
and z-score at the visit were set to missing. WLZ could not be obtained for infants with a length of <45.0 cm at any visit due
to limitations in the WHO standards and were set to missing for that visit (9). All the final models included the following
predictors: arm; site; cluster; interaction between site and cluster; SES; maternal education, parity, BMI (≤22 and >22), and
height (≤150 cm, >150 cm); and paternal BMI (≤22, >22, and missing) and height (≤160 cm, >160 cm, and missing);
birth LAZ <–1; birth LAZ <–2; birth WLZ <–2; infant sex; and low birth weight. Arm 1 maternal participants received the
study supplement starting at least 3 mo prior to conception and continued through delivery; arm 2 started the study
supplement at the end of the first trimester and continued through delivery; arm 3 (control) did not receive study supplement.
Number of infants considered for the combined site analysis according to treatment arm were 713, 773, and 735 for arms 1,
2, and 3, respectively. LAZ, length-for-age z-score; SES, socioeconomic status; WAZ, weight-for-age z-score; WLZ,
weight-for-length z-score.
2 Model R2 = 0.340.
3 Paternal height and BMI had 371 missing records and were included in a separate group: missing group not shown here.
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Treatment arm
Arm 1
Arm 2
Arm 3
SES
High (3–6 present)
Low (0–2 present)
Maternal education
Primary
Secondary
No formal schooling
Parity
≥1
0
Maternal BMI, kg/m2
>22
≤22
Maternal height, cm
>150
≤150
Paternal height,2 cm
>160
≤160
Paternal BMI3
>24
≤24
Birth stunting
Mild (<–1 to ≥–2)
Moderate (LAZ <–2)
None (LAZ ≥–1)
Birth WLZ <–2
No
Yes
Sex
Male
Female
Low birth weight
Yes
No

Adjusted mean
difference (95% CI)
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and anemic women at enrollment (37); and optimized maternal
weight status (associated with the protein energy supplement)
prior to conception and greater gestational weight gain before
12 wk of gestation (38–40). These findings provide targets for
interventions to improve fetal growth and thereby to potentially
improve subsequent growth during the first 2 y of life. Last, we
highlight the finding that maternal education (at least secondary)
emerged as a consistent and modifiable predictor of improved
longitudinal growth (linear and ponderal) and reduced stunting
at 24 mo (5, 7).
The strengths of this analysis include the high percentage
(>95%) of offspring of the WF trial participants who contributed

to the data through 24 mo and supported a rigorous analysis
of longitudinal postnatal growth. The multicountry design of
the original randomized trial is a strength. Although the results
reflect heterogeneous settings and participants, these features also
support generalizability of the findings. Limitations include the
availability of first-trimester gestational age dating from only 3
of the 4 sites and the absence of data on postnatal morbidity
and biochemical indicators of inflammatory, metabolic, and
nutritional status that could potentially have provided insights
into factors driving the linear growth faltering we observed.
However, given the strength of the predictive variables and their
consistency with observations from the literature, we submit
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FIGURE 2 Predictors of length-for-age z-score (LAZ) (2A) and stunting (2B) at 24 mo for infants with gestational age determined by first-trimester
ultrasound. Cross-sectional analyses with linear (robust Poisson) regression for continuous (binary) outcomes were used to identify the major predictors of
linear growth status at 24 mo. Gestational age was determined by first-trimester ultrasound and z-scores were derived from INTERGROWTH-21st fetal growth
charts (10). Total participants n = 1329; by arms 1, 2, 3: n = 438, 478, 413, respectively; by site: Guatemala n = 439, India n = 487, Pakistan n = 403. Model
included adjustment for arm, site, cluster, and interaction between site and cluster. ∗ Birth LAZ <–1 to ≥–2. Adj RR, adjusted RR; Educ, education; Ht, height;
IG, INTERGROWTH-21st standards; LAZ, length-for-age z-score; Mat, maternal; Pat, paternal; PTB, preterm birth; SES, socioeconomic status; SGA, small
for gestational age.
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that the impact of such postnatal factors is unlikely to have
substantially attenuated the findings.
In summary, the sharp downward trajectory of linear growth
after 6 mo of age and the profound stunting rates at 24 mo
underscore the importance of postnatal nutrition (and other
environmental/nutrition-sensitive factors), which surely must be
addressed. The evidence to date, however, suggests the impact of
such interventions will be incremental without attention to the
entire 1000 d. More research is needed to determine whether
additive, or even synergistic, effects could be realized with a
combination of early prenatal and postnatal interventions. With
the strongest predictor of stunting (and length) at 24 mo being
birth length, however, we surmise that substantial improvements
in postnatal growth are likely to depend on improved intrauterine
growth, especially during the critical first trimester.
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